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AbstrAct
Objectives To determine the incidence of clinical, 
cardiac-related endpoints and mortality among patients 
presenting to an emergency or cardiology department with 
non-specific chest pain (NSCP), and who receive testing 
with a high-sensitivity troponin. A second objective was to 
identify risk factors for the above-noted endpoints during 
12 months of follow-up.
Design A prospective multicentre study.
setting Emergency and cardiology departments in 
Southern Denmark.
subjects The study enrolled 1027 patients who were 
assessed for acute chest pain in an emergency or 
cardiology department, and in whom a myocardial 
infarction or another obvious reason for chest pain had 
been ruled out. Patients were enrolled from September 
2014 to June 2015 and followed for 1 year.
Main outcome measures Clinical, cardiac-related 
endpoints (cardiac-related death, acute myocardial 
infarction, unstable angina and coronary revascularisation) 
and all-cause mortality.
results Over a period of 1 year, cardiac-related endpoints 
were found in 19 patients (1.9%): 0 patients experienced 
cardiac-related death, 2 (0.2%) had myocardial infarction, 
4 (0.4%) had unstable angina pectoris and 17 (1.7%) 
underwent coronary revascularisation. All-cause mortality 
was observed in seven patients (0.7%). When compared 
with the general population, the standardised mortality 
ratio did not differ. The risk factors associated with the 
study endpoints included male gender, body mass index 
>25 kg/m2, previous known coronary artery disease, 
hypertension, hypercholesterolaemia, diabetes mellitus 
and the use of statins. A total of 73% of the endpoints 
occurred in males.
conclusion The prognosis for patients with NSCP is 
favourable, with a 1-year mortality after discharge that is 
comparable with the background population. Few clinical 
endpoints took place during follow-up, and those that did 
were predominantly in males.
IntrODuctIOn
Patients with acute chest pain or discomfort 
represent a large proportion of referrals to 
emergency and cardiology departments. 
Although fewer than 20% of these patients 
are diagnosed with an acute myocardial 
infarction (MI),1–4 the absence of one does 
not rule out possible underlying coronary 
artery disease (CAD). CAD is associated with 
20% of all deaths in Europe.5 Discharge 
diagnoses after an admission for acute chest 
pain include the clinical manifestations of 
CAD (unstable angina pectoris (UAP) or 
MI), other cardiac-related diagnoses (aortic 
dissection or pulmonary embolus), non- 
cardiac disorders (gastrointestinal, respiratory 
or musculoskeletal) and non-specific chest 
pain (NSCP). This latter group comprised 
patients who are discharged without a plau-
sible explanation for their symptoms. While 
the former groups are well described in liter-
ature,6 7 patients with NSCP receive compar-
atively little attention, although they are not 
entirely ignored. Previous studies have noted 
that patients with NSCP have frequent contact 
with healthcare systems and high medication 
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strengths and limitations of this study
 ► No patients were lost to follow-up.
 ► Multicentre study enrolling patients from six 
hospitals.
 ► Few events during follow-up.
 ► The cohort was relatively unselected.
 ► The clinical endpoints were based on physician 
assessment and not otherwise validated.
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use.8 Other studies have revealed that 0.6%–0.8% of 
patients with NSCP who are seen in emergency depart-
ment (ED) have a major cardiac event within 30 days of 
discharge.9 10 
In this multicentre study, we examined patients who 
were discharged from an emergency or cardiology depart-
ment with a diagnosis of NSCP after routine clinical care, 
including testing with a high-sensitivity troponin (hsTn). 
The principle objective was to describe the outcomes of 
patients with NSCP with respect to clinical, cardiac-related 
events and all-cause mortality during 1 year of follow-up. A 
second objective was to identify risk factors for predicting 
ischaemic cardiac events in the first year after discharge.
MethODs
Design
The study was structured as a prospective multicentre 
cohort study. Six hospitals in the Region of Southern 
Denmark participated: Aabenraa Hospital, Sonderborg 
Hospital, Odense University Hospital, Svendborg 
Hospital, Vejle Hospital and Kolding Hospital. The study 
enrolled consecutive patients admitted to emergency or 
cardiology departments with acute chest pain or discom-
fort. Patients received a routine physician evaluation that 
included testing with a hsTn assay.
study population
The study included patients aged 30–70 years who were 
referred with chest pain to emergency or cardiology 
departments, and who had at least one hsTn measure-
ment in the first 24 hours following admission. Patients 
were prospectively enrolled during a 9-month period 
from September 2014 to June 2015, and followed until 
June 2016 or for a minimum of 1 year, until emigration, 
or until death.
Patients were identified for study eligibility by searching 
daily through the central biochemical database, which 
stores laboratory results for patients in the Region of 
Southern Denmark. An hsTn T value <14 ng/L or an 
hsTn I value <25 ng/L was required for inclusion. The 
attending physician’s discharge diagnosis was recorded, 
and patients were considered to have NSCP if any of the 
following international diagnosis code (International 
Classification of Diseases 10 (ICD-10) codes) were given: 
DR072 (precordial chest pains), DR073 (other chest 
pains), DZ034 (observation for MI) or DZ035 (observa-
tion for coronary disease). A structured phone interview 
was completed within 3 days of discharge.
Patients were excluded from the study if they were not 
contacted within 3 days of discharge (after three calls were 
made on different days and at different times), if they did 
not understand either Danish or English, if they were 
intoxicated, if they were pregnant, if they had an obvious 
cause for their chest pain or discomfort or if they had 
normal coronary angiography during the index admis-
sion. Additionally, patients were excluded from the study 
if they did not provide consent for follow-up or if medical 
records from their index admission were unavailable.
Material and data
A phone interview was conducted by the first author or 
by one of the two nurses who participated in the study. 
Patients received standardised questions pertaining to 
symptoms that they had at the time of index contact, 
as well as questions regarding their medical history and 
their risk factors for CVD. The study questionnaire was 
validated for interobserver validity, with a finding of 72% 
agreement between interviewers. Following the interview, 
patients were mailed a consent form requesting access to 
their health records, which contained clinical, laboratory 
and imaging results.
Definitions
Smoking was quantified in pack years, with one pack year 
defined by 20 cigarettes, per day, per year. Hypertension, 
hypercholesterolaemia and diabetes were self-reported 
conditions. Family history was considered positive if any 
first degree relative, regardless of age, had known CVD. 
Statins were identified using the Anatomical Therapeutic 
Chemical code C10AA.
The medical history was established using ICD-10 
diagnoses from admissions that occurred in the 10 years 
preceding the index visit. Subsequently, these were 
grouped into clinical categories: prior CAD included the 
ICD-10 diagnoses for acute and chronic ischaemic heart 
disease; peripheral arterial disease (PAD) included the 
diagnostic codes for intermittent claudication and athero-
sclerotic disease; ischaemic cerebral disease included the 
codes for apoplexy and transitory cerebral ischaemia and 
supraventricular tachycardia included the codes for atrial 
fibrillation and atrial flutter.
Since comorbidity is a recognised confounding variable 
for CVD, Charlson comorbidity index scores were calcu-
lated for participants.11 12 This was done using the primary 
discharge diagnosis from admissions that occurred in the 
10 years prior to the index visit. The diagnosis specified 
by the attending physician at the time of admission(s) was 
the recorded primary discharge diagnosis; this was not 
validated by a chart review or other means.
Data on prescription medications were obtained using 
information accessed from the Odense Pharmacoepide-
miologic Database.13 Patients were considered to have 
used a statin if they had filled a prescription for one in 
the 3 months before the index admission.
clinical outcomes
The primary outcome was a composite endpoint of 
all-cause mortality and clinical cardiac-related endpoints. 
Patients were classified as having a clinical cardiac-related 
endpoint if any of the following occurred during the year 
of follow-up: cardiac death, acute MI, UAP, or coronary 
revascularisation.
The endpoints were identified using information 
collected from the National Patient Register14 and the 
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Civil Registration System,15 which included diagnostic 
codes entered by attending physicians.
hstn assays
The study used the hsTn assays hsTnI or hsTnT, both 
with a 99th percentile cut-off point. Odense University 
Hospital used hsTnI, which was analysed by Abbot Diag-
nostics Architect with an upper reference limit of 25 ng/L. 
The 10% coefficient of variation (CV) was 5 ng/L and the 
MI decision limit was ≥25 ng/L.16 All other participating 
hospitals used hsTnT, which was analysed by Roche Diag-
nostic Elecsys 2010, modular analytics E170, Cobas e411 
and Cobas e601. The 99th percentile cut-off value was 
14 ng/L, the 10% CV 13 ng/L and the MI decision limit 
was ≥ 14 ng/L.17
sample size calculations
With a sample of 1298 patients, the study had a power of 
80% and a two-sided CI of 95% for identifying risk factors 
that occurred 20% more frequently in patients with the 
pre-specified outcomes of all-cause mortality and clin-
ical, cardiac-related endpoints. We assumed that clinical 
outcomes would occur in 2% of patients who were unex-
posed to the risk factors of interest, and in 5% of patients 
who were exposed to the risk factors.
statistics
Continuous variables were organised into categorical 
subgroups, with the exception of age, which was reported 
in medians with interquartile ranges. Receiver-operating 
characteristic curves were calculated for each variable to 
identify acceptable cut-off points. Categorical variables 
were reported in frequency and percentages, and the 
Pearson’s χ2 test was used to make intergroup compar-
isons. Any unobtained laboratory data were analysed as 
missing data.
Patients were followed until the first clinical endpoint 
occurred. Unadjusted event data were shown as a failure 
plot. The prognostic effect of variables on the clinical 
endpoints was analysed by univariate cox regression. 
More variables were tested than reported, but all signif-
icant variables were reported, in addition to select, clin-
ically relevant, non-significant variables. A P value <0.05 
was considered significant.
From Statistics Denmark, we obtained population size 
and mortality among people aged 30–70 years living in 
the Region of Southern Denmark in 2015. We used this 
information to calculate the expected mortality ratio for 
the study population. The observed mortality ratio in 
the NSCP study population was then compared with the 
expected mortality ratio, and adjusted for age and gender 
to estimate the standardised mortality ratio in the study 
sample compared with the general population. Data were 
analysed using STATA v.14.2 0 (Stata, College Station, 
Texas).
Written, informed consent to access records was sent to 
participants after their phone interviews and confirmed 
prior to accessing their records.
results
Among 1213 eligible patients, 1027 returned their 
consent forms and were included in the study. Figure 1 
shows the flow chart for patient inclusion and exclusion. 
Patients who were eligible for study and completed the 
interview, but did not return their consent, are referred 
to as non-participants. A comparison between partici-
pants (n=1027) and non-participants (n=186) showed 
a significant difference in median age and gender: 
the median age for participants was 54 years (IQR: 
47–62) versus 47 years (IQR: 39–56) for non-partici-
pants, P=0.001; females comprised 568 (55%) of partic-
ipants and 90 (48%) of non-participants, P=0.081. Two 
patients left Denmark before the end of the follow-up 
period.
Baseline characteristics for the participants are shown 
in table 1. Patients with a clinical endpoint were signifi-
cantly older with a median age of 61 (IQR: 47–62), were 
predominantly male (73%), had a Charlson score ≥1, 
used a statin and had more vascular comorbidity at base-
line compared with patients who did not experience a 
clinical endpoint.
Table 2 lists study outcomes after 30 days and 1 year. 
At the 30-day follow-up, all-cause mortality was zero (0%, 
95% CI: 0% to 0.3%), two participants had an MI (0.2%, 
95% CI: 0% to 0.5%), none had UAP (0%, 95% CI: 0% 
to 0.3%) and four underwent coronary revascularisation 
(0.4%, 95% CI: 0.01% to 0.8%). The 30-day composite 
endpoint of all-cause mortality and clinical, cardiac-re-
lated endpoints was experienced by five patients (0.5%, 
95% CI: 0.1% to 0.9%).
At the 1-year follow-up, a total of seven patients in 
the cohort had died (0.7%, 95% CI: 0.2% to 1.2%). 
Compared with the general population, the standardised 
mortality ratio was 1.2 (95% CI: 0.5 to 2.4). The number 
of patients with clinical, cardiac-related endpoints was 19 
(1.9%; 95% CI: 1.0% to 2.7%). During this study period, 
no cardiac-related death was observed (0%, 95% CI: 0% to 
0.3%), 2 patients (0.2%, 95% CI: 0% to 0.5%) had an MI, 
4 patients (0.4%, 95% CI: 0.01% to 0.1%) experienced 
UAP and 17 patients (1.7%; 95% CI: 0.9% to 2.4%) under-
went coronary revascularisation. In total, 26 patients had 
30 events, such that the composite endpoint of all-cause 
mortality and clinical, cardiac-related endpoints occurred 
in 26/1027 patients (2.5%, 95% CI 1.6% to 3.5%). A total 
of 19 (73%) of these composite endpoints occurred in 
male patients. The difference became more distinct with 
time, as demonstrated in the accumulated endpoints plot 
(figure 2), and depicted over the total length of the study 
(1.4 years).
Table 3 shows the HR for risk factors and outcomes after 
1 year, as well as the CI for all clinical events, cardiac-re-
lated events and all-cause mortality. Whereas a univar-
iate analysis was performed, a multivariate analysis was 
omitted due to the lack of clinical events. Variables signifi-
cantly associated with clinical events included gender, a 
body mass index (BMI) >25 kg/m2, a Charlson score >1, 
pre-existing CAD, combined ischaemic comorbidity (a 
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Figure 1 Flow chart for inclusion of study patients. CD, cardiology department; ED, emergency department; hsTn, high-
sensitivity troponin. 
composite value that included CAD, ischaemic cerebral 
disease and PAD), hypertension, hypercholesterolaemia, 
diabetes and the use of statins. Of note, cholesterol labo-
ratory values could not be obtained for 15% of study 
participants.
DIscussIOn
Prognosis for patients with nscP
Patients with NSCP attract relatively little research atten-
tion. However, in this cohort study of 4289 patients, 
patients with NSCP represented nearly 25% of all patients 
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Table 1 Descriptive baseline characteristics
Total No clinical endpoint
At least one clinical 
endpoint
P valuen=1027 (%) n=1001 (%) n=26 (%)
Sex
  Female 568 (55) 561 (56) 7 (27) 0.003
  Male 459 (45) 440 (44) 19 (73)
Median age (IQR), years 54 (47–62) 54 (47–62) 61 (53–66) 0.010
  30–39 102 (10) 102 (10) 0 (0) 0.020
  40–49 247 (24) 243 (24) 4 (15)
  50–59 325 (32) 319 (32) 6 (23)
  >60 353 (34) 337 (34) 16 (62)
Charlson score
  0 783 (76) 770 (77) 13 (50) 0.001
  ≥1 244 (24) 231 (23) 13 (50)
Smoking status
  Previous smoker 338 (33) 334 (33) 4 (15) 0.002
  Current smoker 257 (25) 243 (24) 14 (54)
  Never smoked 432 (42) 424 (43) 8 (31)
Statin use 213 (21) 202 (20) 11 (42) 0.006
Cardiovascular comorbidity
  Coronary artery disease 166 (16) 156 (16) 10 (39) 0.002
  Peripheral artery disease 19 (2) 16 (2) 3 (12) 0.001
  Ischaemic cerebral disease 49 (5) 47 (5) 2 (8) 0.479
  Supraventricular tachycardia 53 (5) 51 (5) 2 (8) 0.554
P values are for χ2 test between patients with and without a clinical endpoint.
Table 2 Endpoints at the 30-day and 1-year follow-up
30 days 1 year
n=5 % n=26 %
Death 0 0 (0.0–0.3) 7 0.7 (0.2–1.2)
Cardiac-related 
death
0 0 (0.0–0.3) 0 0.0 (0.0–0.3)
Myocardial 
infarction
2 0.2 (0.0–0.5) 2 0.2 (0.0–0.5)
Unstable angina 
pectoris 
0 0 (0.0–0.3) 4 0.4 (0.0–0.8)
Revascularisation 4 0.4 (0.1–0.8) 17 1.7 (0.9–2.4)
Composite 
endpoint
5 0.5 (0.1–0.9) 26 2.5 (1.6–3.5)
Figure 2 Failure plot with combined endpoints for the total 
cohort.
presenting to emergency or cardiology departments with 
chest pain or discomfort; they thus deserve additional 
focus.
This study found that patients with NSCP have a 1-year 
all-cause mortality of 0.7% and a risk of a clinical, cardi-
ac-related endpoint of 1.9%. In 2015, mortality for the 
general population, when adjusted for age and gender, 
was 1.2 (CI: 0.5 to 2.4).18 There was no significant mortality 
difference between the patients with NSCP enrolled in 
this study and the general population; this confirms the 
favourable prognosis for patients with NSCP discharged 
from emergency or cardiology departments.
The results of our study are supported by two other 
studies that examined patients with NSCP.9 10 The first 
study showed that 30 days after ED discharge, 0.5% 
of patients with NSCP had an MI, 0.3% experienced 
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Table 3 HR for exposure variables and endpoints during 
1 year of follow-up
Characteristics 
All clinical 
events 
(n = 26) 
Clinical, cardiac-
related endpoint 
(n = 19) 
Age (years)
  40+ 1 1
  50+ 1.1 (0.3–4.0) 1.0 (0.3–3.5)
  60+ 2.8 (0.9–8.4) 1.8 (0.6–5.6)
Male 3.4 (1.4–8.1) 4.7 (1.6–14.0)
BMI >25 kg/m2 3.0 (1.0–7.6) 4.6 (1.1–19.7)
Charlson score ≥ 1 3.2 (1.5–6.9) 1.9 (0.7–4.8)
Smoking >12 package 
years
1.9 (0.8–4.3) 2.1 (0.8–5.3)
Alcohol >2 U/week 0.8 (0.4–1.7) 0.9 (0.3–2.1)
Comorbidity
  Coronary artery disease 3.3 (1.5–7.3) 3.8 (1.5–9.5)
  Ischaemic cerebral 
disease
1.7 (0.4–7.0) 1.1 (0.2–8.3)
  Peripheral arterial 
disease
7.4 (2.2–24.5) 3.1 (0.4–23)
  Supraventricular 
tachycardia
1.5 (0.4–6.4) 1.0 (0.2–7.6)
  Combined ischaemic 
comorbidity*
4.0 (1.9–8.7) 3.6 (1.5–8.9)
  Hypertension 5.2 (2.1–12.8) 5.8 (1.9–17.5)
  Hypercholesterolaemia 2.5 (1.1–5.9) 6.0 (1.7–20.6)
  Diabetes 5.0 (2.2–11.6) 5.2 (2.0–13.7)
Family history of CVD 1.7 (0.7–3.8) 1.6 (0.6–4.0)
Triglycerides ≥1 mmol/L 1.4 (0.5–3.8) 1.0 (0.4–2.7)
Total cholesterol >5 mmol/L 0.5(.2–1.2) 0.4 (0.2–1.1)
LDL >3 mmol/L 0.5 (0.2–1.1) 0.3 (0.1–1.0)
HDL <1 mmol/L 2.1 (0.8–5.5) 3.0 (1.1–8.5)
Statin use 2.8 (1.3–6.2) 4.3 (1.8–10.6)
*Combined ischaemic comorbidity consists of coronary artery 
disease, ischaemic cerebral disease and peripheral vascular 
disease. 
BMI, body mass index; CVD, cardiovascular disease; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein.
unplanned revascularisation and 0.2% died.9 The 
second study, a Swedish population-based study that 
was conducted after implementation of an hsTn assay,10 
found that 30 days after ED discharge 0.3% of patients 
with NSCP had experienced an MI, 0.3% had undergone 
coronary revascularisation and 0.2% had died. These 
studies reinforce the notion that when clinical events do 
occur, they tend to do so soon after discharge.10 
In contrast, other studies have contracted our find-
ings. Jordan et al19 found that patients with NSCP had an 
increased risk of cardiac events after discharge. Of note, 
this study did not impose an age limitation, the definition 
of cardiovascular events included a greater number of 
diagnoses (such as stroke and periphery arterial disease) 
and the follow-up time was longer (up to 5.5 years). More 
importantly, it is unclear where enrolled patients had a 
normal troponin, and the type of troponin assay would 
have been markedly different from what is currently used 
since the inclusion period for this study was from 2002 
to 2009. Similarly, Bandstein et al demonstrated a higher 
event rate for MI when compared with our study. In a 
cohort of patients aged more than 25 years who presented 
to the ED with chest pain and had a single hsTn T <14, 
1.2% (146/12 033) of patients experienced an MI in 
the year after the index visit.20 The difference between 
this study and our own could be explained by age differ-
ences between the cohorts.21 Finally, Kelly and Klim22 
found that patients who presented to the ED with chest 
pain, but who had a normal ECG and normal troponins, 
had a mortality rate of 3% after a median follow-up of 
48 months. In addition, during this time frame 0.6% of 
the cohort had an MI and 3.1% underwent revascularisa-
tion. Qualifying these findings was again the fact that the 
cohort was different. Specifically, the cohort was younger, 
excluded individuals with known CAD and was 55% male. 
Furthermore, the study employed an older generation of 
troponin assay when compared with the hsTn used in our 
study.
risk factors for future cardiac-related events among the nscP 
with nscP
To our knowledge, this is the first study to assess risk 
factors in NSCP after hsTn implementation. Our study 
demonstrated that the following variables influence the 
1-year risk of a cardiac event: male gender, BMI >25 kg/
m2, known CAD, other vascular comorbidity, hyperten-
sion, hypercholesterolaemia, diabetes mellitus and the 
use of statins. A total of 73% of the composite endpoints 
occurred in males, confirming existing knowledge 
that male gender is a significant risk factor for CAD. 
Not surprisingly, most cardiovascular risk stratification 
tools, such as the Systematic Coronary Risk Evaluation 
(SCORE), already include gender as a variable in their 
scoring systems.23
Omstedt et al 9 showed that the risk of a future MI, 
unplanned revascularisation and death in patients with 
NSCP are associated with age, previous MI, heart failure, 
hypertension, stroke, hyperlipidaemia, diabetes mellitus 
and male gender. These risk factors were recognised in 
our study. Nejatian et al’s study10 showed that admitted 
patients had a worse prognosis than directly discharged 
patients. However, admitted patients had a greater 
number of cardiovascular risk factors, thereby demon-
strating that the clinical assessment remains a critical 
element of chest pain assessment, and that hsTn cannot 
be considered a stand-alone test when attempting to rule 
out acute MI.
strength and limitations
The strength in our study is that it was a multicentre 
study with prospective data collection. Moreover, 
outcome data were obtained from national registration 
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systems that are linked to individual civil registration 
numbers.14 15
However, our study does have some limitations. First, 
the cohort excluded patients who had a coronary angi-
ography performed during index contact. We chose to 
exclude these patients as clearly the evaluating physician 
suspected CAD rather than NSCP. UAP, which was one of 
the study’s cardiac-related endpoints, is a clinician-depen-
dent diagnosis and carries the risk of misclassification of 
patients that should have a diagnosis of NSCP. Second, 
186 patients did not return their consent, the reasons for 
which were unexplored and hence unclear. Third, we 
only included patients aged 70 years as it is known that 
increasing age is an important risk factor for CAD. This 
could partially explain the difference in findings between 
our study and other studies, as most other studies did not 
have an upper age limit.9 10 20 Finally, the main study limita-
tion was the lack of events that occurred during follow-up; 
unfortunately, this restricted our ability to study risk 
factors. While a sample size was calculated before begin-
ning the study, the outcome rates from existing literature 
overestimated the expected outcome rate.
This study demonstrates that patients with NSCP have a 
good prognosis, with very few patients at risk of death or a 
clinical, cardiac-related endpoint. The lack of endpoints 
may help clinicians reassure patients with NSCP, thereby 
reducing patient anxiety and the risk of readmission. 
Future research could focus on patients with NSCP using 
the risk factors identified in this study, or alternatively 
they could focus on how to reduce the frequency of NSCP 
patient visits to emergency and cardiology departments.
cOnclusIOn
Our study demonstrates that patients with NSCP have a 
good prognosis on discharge. Among NSCP patients with 
cardiac-related endpoints, male gender is a significant 
risk factor for an adverse outcome among patients with 
a BMI >25 kg/m2, a history of CAD or another vascular 
comorbidity, hypertension, hypercholesterolaemia, 
diabetes mellitus and who use statins. Patients who are 
discharged from the hospital after an initial assessment 
for acute chest pain, without further investigation, are 
usually evaluated correctly and can be reassured of a posi-
tive prognosis.
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